1 minute reading time (47 words)

FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device

Theranica, a bio-medical technology company developing advanced electroceuticals for migraine and other pain disorders, announced today that the U.S. Food and Drug Administration (FDA) granted a De Novo request for its smartphone-controlled electroceutical, Nerivio Migra┬«, utilizing Remote Electrical Neuromodulation for the acute treatment of migraine. 

Related Posts

Want more pain resources? Check out our library of on-demand education, upcoming events, and more.

Learn More